Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded by BidaskClub

BidaskClub cut shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a sell rating in a research note released on Wednesday morning, BidAskClub reports.

A number of other equities research analysts also recently weighed in on RARE. Leerink Swann reaffirmed a positive rating and set a $85.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 4th. ValuEngine downgraded Ultragenyx Pharmaceutical from a buy rating to a hold rating in a report on Thursday, September 5th. Piper Jaffray Companies set a $75.00 price objective on Ultragenyx Pharmaceutical and gave the company a buy rating in a report on Wednesday, September 4th. Wedbush reaffirmed a buy rating and set a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $74.23.

RARE traded down $0.59 on Wednesday, hitting $44.10. 805,509 shares of the stock traded hands, compared to its average volume of 581,190. Ultragenyx Pharmaceutical has a 52 week low of $37.44 and a 52 week high of $90.98. The company has a current ratio of 9.32, a quick ratio of 9.14 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average price of $55.52 and a two-hundred day moving average price of $61.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The firm had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. During the same period in the previous year, the company posted ($1.06) earnings per share. The company’s quarterly revenue was up 88.8% compared to the same quarter last year. As a group, research analysts predict that Ultragenyx Pharmaceutical will post -7.03 earnings per share for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average cost of $43.63 per share, with a total value of $218,150.00. Following the acquisition, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 1,226 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $61.50, for a total value of $75,399.00. The disclosure for this sale can be found here. 7.80% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $5,055,000. Cowen Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 13.3% in the 2nd quarter. Cowen Inc. now owns 34,000 shares of the biopharmaceutical company’s stock worth $2,159,000 after acquiring an additional 4,000 shares in the last quarter. United Services Automobile Association boosted its holdings in shares of Ultragenyx Pharmaceutical by 0.7% in the 2nd quarter. United Services Automobile Association now owns 31,483 shares of the biopharmaceutical company’s stock worth $1,999,000 after acquiring an additional 215 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 6,239.7% in the 2nd quarter. Nuveen Asset Management LLC now owns 275,081 shares of the biopharmaceutical company’s stock worth $17,467,000 after acquiring an additional 270,742 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Ultragenyx Pharmaceutical by 31.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after acquiring an additional 1,110,316 shares in the last quarter.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Article: How do CD ladders protect against rising interest rates?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.